Metastatic kidney cancer

Disease Description (Causes and Symptoms)

• Definition summary: Metastatic kidney cancer refers to renal cell carcinoma (RCC) in which cancer cells originating in the kidney have spread to other organs (such as the lungs, bones, liver, or brain) through the bloodstream or lymphatic system. It accounts for approximately 2% of newly diagnosed tumors worldwide, and the most common histologic type of kidney cancer is clear-cell carcinoma (approximately 80% of cases).
• Brief pathophysiology: Most cases originate in the epithelium of the renal tubules, mainly the proximal tubules. Activation of the HIF-VEGF signaling pathway due to abnormalities such as VHL gene alterations promotes angiogenesis and tumor growth, followed by metastasis through the vascular and lymphatic systems.
• Major causes and risk factors: Smoking, obesity, hypertension, long-term hemodialysis for chronic renal failure (ESRD), family history (e.g., von Hippel–Lindau), certain genetic predispositions, and environmental factors.
• Typical symptoms: Hematuria (the most common), flank pain, weight loss, and fatigue. Symptoms caused by metastasis may include cough/shortness of breath (lung metastasis), bone pain (bone metastasis), and headache/neurological deficits (brain metastasis). Tumor-related hormonal/paraneoplastic syndromes may also cause hypertension, hypercalcemia, liver-function abnormalities, and other problems.

Treatment Methods

• General principles: Individualized treatment is selected according to the stage (extent of the primary tumor and metastases), the patient’s overall condition (performance status, kidney function, and comorbidities), histologic type, and molecular markers.
• Treatment of localized disease (nonmetastatic or limited metastatic disease): Radical nephrectomy (partial or total nephrectomy) is standard. Selected metastasectomy (such as of lung or bone lesions) may also contribute to improving survival in some patients.
• Standard treatment for metastatic/systemic disease (recent guideline summary)
  • Immune checkpoint inhibitor (ICI)-based combination therapy: Examples include nivolumab + ipilimumab (particularly for intermediate- and poor-risk groups), pembrolizumab + axitinib, pembrolizumab + lenvatinib, and nivolumab + cabozantinib — widely used as first-line treatment options.
  • Targeted therapy (tyrosine kinase inhibitors, VEGF pathway inhibitors, and mTOR inhibitors): sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, lenvatinib, everolimus, temsirolimus, and others — used alone or in combination with immunotherapy.
  • Traditional cytotoxic chemotherapy has limited effectiveness in kidney cancer.
  • Local treatment/symptom relief: Radiation therapy (to relieve pain or local symptoms from bone or brain metastases), percutaneous radiofrequency/cryoablation, and selected metastasectomy.
  • Complications such as hypercalcemia, anemia, and infection are treated with fluids and medications. Bone-modifying agents (bisphosphonates and denosumab) may be considered for bone metastases.
• Monitoring during treatment and management of adverse effects:
  • Targeted therapy: Monitoring is required for hypertension, proteinuria, gastrointestinal symptoms, skin reactions, liver-function abnormalities, and others.
  • Immune checkpoint inhibitors: Immune-related adverse events may occur in the skin, intestines, lungs, liver, endocrine system, and other organs — when recognized early, immunosuppressive treatment such as steroids may be required.
• Lifestyle management and precautions:
  • Quit smoking, control body weight, manage blood pressure and diabetes, and preserve kidney function (avoid dehydration and nephrotoxic medications).
  • Regular blood tests and monitoring of liver function, thyroid function, blood pressure, and proteinuria are essential during treatment.
  • Prevent infections (particularly when immunosuppressed) and consult about vaccination (confirm recommended timing and types).

Checklist Before an Outpatient Visit (Including Items to Bring and Sample Questions)

• Items/documents to bring:
  • A list of all medications currently being taken (including prescription drugs, OTC medications, and supplements)
  • Past medical history and surgical records (particularly information related to kidney surgery and hemodialysis)
  • Recent test results (blood tests, liver and kidney function, electrolytes) and imaging CDs or reports (ultrasound, CT, MRI, PET, etc.)
  • Pathology report (histologic examination results of the primary tumor)
  • A symptom diary (hematuria, weight changes, fatigue level, location and intensity of pain, etc.) and recent weight and blood pressure records
• Information to tell the doctor in advance during the outpatient visit:
  • Whether recent bleeding, cough, shortness of breath, or neurological symptoms have occurred
  • Whether the patient is receiving dialysis and the date of the last dialysis session, if applicable
  • Previous experience with immunotherapy, targeted therapy, or radiation therapy and any adverse effects
• Sample questions (phrases patients can use themselves)
  • “What are the results of my most recent tests regarding the metastatic lesions I currently have (location and size)?”
  • “What is the goal of the treatment you recommend for me this time (cure, symptom relief, or prolonging survival)?”

General Sample Questions to Ask the Doctor

• What are the side effects of this medication, and what should I do if a problem occurs?
• What is my individual prognosis (expected survival), and what are the main factors that affect it?
• What should I be careful about in daily life (exercise, diet, alcohol consumption, returning to work, etc.)?

Disease-Specific Sample Questions

• In my case, is it recommended to perform cytoreductive nephrectomy (nephrectomy/cytoreductive nephrectomy) first, or would it be better to start systemic treatment immediately?
• Considering my kidney function (or history of dialysis) and comorbidities, which systemic treatment (immunotherapy or targeted therapy) is most appropriate, and what is the risk of adverse effects?

(Note: Diagnostic and treatment decisions should be made in consultation with the treating medical team based on the individual patient’s circumstances, disease stage, performance status, and institutional guidelines.)